Cost-benefit analysis of hepatitis B virus serological and nucleic acid testing in blood donors
10.13303/j.cjbt.issn.1004-549x.2023.01.014
- VernacularTitle:献血者血液乙肝病毒血清学和核酸筛查成本效益分析
- Author:
Xianlin YE
1
;
Wen XIONG
1
;
Tong LI
1
;
Ran LI
1
;
Liqing HUANG
1
;
Jinfeng ZEN
1
Author Information
1. Shenzhen Blood Center, Shenzhen 518035, China
- Publication Type:Journal Article
- Keywords:
hepatitis B virus;
hepatitis B surface antigen;
blood donors;
nucleic acid test;
nucleic acid test;
individual;
moni-pool
- From:
Chinese Journal of Blood Transfusion
2023;36(1):56-59
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 In an effort to prevent transfusion-transmitted hepatitis B infection, universal HBsAg screening, HBsAg+ MP nucleic acid test(NAT) for HBV and HBsAg + individual(ID) NAT were analyzed for cost-effectiveness. 【Methods】 On the basis of screening data and the documented parameter, the number of window period infections, chronic infections and occult infections was constructed, and cost-benefit analysis was conducted. 【Results】 Of 132 208 donations, the yield rate of ID NAT for HBsAg-/DNA+ (0.11%) was significantly higher than HBsAg+ MP NAT(0.058%). Furthermore, the predicted preventing transfusion transmitted HBV cases by ID NAT is 1.25 times as that by MP-6 NAT, so did the benefits. The cost-benefit of the three screening models were 1∶63.6、1∶28.6 and 1∶53.4. 【Conclusion】 Universal HBsAg in combination with ID HBV NAT screening was the most effective among all screening strategy. It is necessary to applied HBsAg and ID HBV NAT screening for the safety of blood transfusion.
